AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 179 filers reported holding AERIE PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.80 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $17,027,000 | +84.8% | 1,125,395 | -8.4% | 2.31% | +111.8% |
| Q2 2022 | $9,214,000 | -29.5% | 1,228,525 | -14.4% | 1.09% | -13.6% |
| Q1 2022 | $13,066,000 | +127.7% | 1,435,876 | +75.7% | 1.26% | +135.1% |
| Q4 2021 | $5,738,000 | -64.2% | 817,377 | -41.9% | 0.54% | -66.5% |
| Q3 2021 | $16,029,000 | -25.8% | 1,406,042 | +4.1% | 1.60% | -27.4% |
| Q2 2021 | $21,616,000 | +32.4% | 1,350,183 | +47.7% | 2.20% | +26.7% |
| Q1 2021 | $16,331,000 | +62.5% | 913,884 | +22.9% | 1.74% | +54.7% |
| Q4 2020 | $10,049,000 | -36.6% | 743,852 | -44.8% | 1.12% | -45.8% |
| Q3 2020 | $15,854,000 | -38.5% | 1,346,983 | -22.9% | 2.08% | -41.4% |
| Q2 2020 | $25,787,000 | +27.3% | 1,747,101 | +16.4% | 3.54% | +8.3% |
| Q1 2020 | $20,260,000 | -49.9% | 1,500,757 | -10.4% | 3.27% | -18.9% |
| Q4 2019 | $40,467,000 | +76.8% | 1,674,258 | +40.6% | 4.03% | +59.4% |
| Q3 2019 | $22,883,000 | +248.8% | 1,190,606 | +436.3% | 2.53% | +290.7% |
| Q2 2019 | $6,560,000 | +2667.9% | 221,990 | +4339.8% | 0.65% | +2296.3% |
| Q1 2019 | $237,000 | – | 5,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |